Matthias Lohr
Overview
Explore the profile of Matthias Lohr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
3663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Freedman S, de-Madaria E, Singh V, Bruckert E, Lohr M, Sutton R, et al.
Curr Med Res Opin
. 2022 Nov;
39(1):37-46.
PMID: 36384356
Objective: The objective of this study is to generate a core clinical dataset (CD) containing the minimum acceptable amount of information that should be collected for each patient presenting with...
12.
Klatte D, Wallace M, Lohr M, Bruno M, van Leerdam M
Best Pract Res Clin Gastroenterol
. 2022 Aug;
58-59:101783.
PMID: 35988957
Pancreatic cancer is one of the deadliest malignancies. Therefore, there is an urgent need to detect pancreatic cancer in an earlier stage to improve outcomes. A variety of hereditary cancer...
13.
Erchinger F, Tjora E, Nordaas I, Dimcevski G, Olesen S, Jensen N, et al.
United European Gastroenterol J
. 2022 Aug;
10(8):844-853.
PMID: 35981311
Objectives: Pancreatic exocrine insufficiency (PEI) is a common complication in patients with chronic pancreatitis (CP), leading to increased morbidity and mortality if not treated adequately. Pancreatic enzyme replacement therapy|pancreas enzyme...
14.
Vitaloni M, Michl P, Lohr M, Stunt A, Rzadkowska P, Backman E, et al.
J Patient Exp
. 2022 Jul;
9:23743735221112633.
PMID: 35846247
Pancreatic cancer is a disease requiring urgent attention from governments and policymakers. Recently, a state of emergency has been declared for this cancer-being the fourth most common cause of cancer...
15.
Balduzzi A, Salvia R, Lohr M
United European Gastroenterol J
. 2022 Feb;
10(2):145-146.
PMID: 35122677
No abstract available.
16.
Bergquist E, Kartalis N, Sparrelid E, Lohr M, Ghorbani P
Lakartidningen
. 2022 Jan;
118.
PMID: 35060112
Pancreatic cysts are common. Some harbor malignant potential but are not always distinguishable from benign lesions. Premalignant cysts offer an opportunity for preventive surgery. Pancreatic surgery is associated with morbidity...
17.
Gundel B, Liu X, Lohr M, Heuchel R
Front Cell Dev Biol
. 2021 Nov;
9:741162.
PMID: 34746135
Pancreatic ductal adenocarcinoma (PDAC) is one of the most overlooked cancers despite its dismal median survival time of 6 months. The biggest challenges in improving patient survival are late diagnosis...
18.
Yu J, Song H, Ekheden I, Lohr M, Ploner A, Ye W
Cancer Epidemiol Biomarkers Prev
. 2021 Sep;
30(11):2088-2095.
PMID: 34497088
Background: It remains open whether gastric precancerous lesions are associated with an elevated risk of pancreatic cancer. Our aim was to investigate the association between gastric mucosal status and pancreatic...
19.
Michl P, Lohr M, Neoptolemos J, Capurso G, Rebours V, Malats N, et al.
United European Gastroenterol J
. 2021 Aug;
9(7):860-871.
PMID: 34431604
Background: Pancreatic ductal adenocarcinoma is the deadliest cancer worldwide with a 98% loss-of-life expectancy and a 30% increase in the disability-adjusted life years during the last decade in Europe. The...
20.
Liu X, Gundel B, Li X, Liu J, Wright A, Lohr M, et al.
Transl Oncol
. 2021 May;
14(7):101107.
PMID: 33946033
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, partly due to the dense desmoplasia and a lack of suitable model systems to study. In the present work,...